Sign In
Buy CARM
$0.0001
+0 (+0%)
At Close: Jun 03, 2026
Here's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now
10:56am, Thursday, 04'th Apr 2024
CARISMA THERAP (CARM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among
Carisma Therapeutics to Present at Upcoming Conferences
07:00am, Wednesday, 03'rd Apr 2024
PHILADELPHIA , April 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing in
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
08:35am, Monday, 01'st Apr 2024
Company to prioritize CT-0525 as its anti-HER2 CAR-M product candidate and will cease further development of CT-0508 Other prioritized pipeline programs include the Company's in vivo CAR-M collaborati
Carisma Therapeutics Announces Changes to its Board of Directors
07:00am, Monday, 01'st Apr 2024
Appointment of John Hohneker, M.D. Resignation of Chidozie Ugwumba PHILADELPHIA , April 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-sta
Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
05:00pm, Thursday, 21'st Mar 2024
PHILADELPHIA , March 21, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing i
Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference
07:30am, Wednesday, 28'th Feb 2024
PHILADELPHIA , Feb. 28, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing i
Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
07:00am, Thursday, 21'st Dec 2023
PHILADELPHIA , Dec. 21, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing in
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
07:00am, Thursday, 14'th Dec 2023
First lead candidate to address a solid tumor indication with significant unmet medical need Supportive pre-clinical proof of concept data reported at SITC 2023 that demonstrated feasibility, tolerabi
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte
07:00am, Tuesday, 28'th Nov 2023
CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting First patient expected to be treated in the first half of 2024 PHILADELPHIA , Nov. 28, 2023 /PRNewswire/ -- Caris
Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference
07:30am, Wednesday, 22'nd Nov 2023
PHILADELPHIA , Nov. 22, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn
Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
07:30am, Thursday, 09'th Nov 2023
Presented updated data from Phase 1 clinical trial of CT-0508 at CAR-TCR Summit, further supporting CAR-M safety, feasibility and mechanism of action Selected clinical candidate for CT-1119, an anti-m
Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC
09:25am, Tuesday, 31'st Oct 2023
- Data demonstrate feasibility, tolerability, and early efficacy of mRNA/LNP in vivo CAR-M therapy in pre-clinical models of metastatic solid tumors - Proof of concept achieved for platform under the
Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023
09:11am, Wednesday, 25'th Oct 2023
-Late-breaking abstract to be presented on November 3 rd at 11:30 am PT highlighting pre-clinical data with Moderna -Two additional pre-clinical data abstracts highlighting next-generation enhancement
3 Top Under-$5 Stocks for Strong Gains and Positive Outlook
02:52pm, Thursday, 12'th Oct 2023
To clearly set expectations from the get-go, these top stocks under $5 represent extraordinary risks. As either small or even micro-capitalization enterprises, you automatically should assume volatili
Carisma Therapeutics to Present at Upcoming Investor Conferences
08:30am, Tuesday, 05'th Sep 2023
PHILADELPHIA , Sept. 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn
